ストックスクリーナーアプリを入手
7.911
3.96%
0.301
アフターアワーズ：
7.91
-0.0010
-0.01%
Ocular Therapeutix Inc (OCUL) 最新ニュース
How To Trade (OCUL) - news.stocktradersdaily.com
Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24% - simplywall.st
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM - openPR.com
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listin - GuruFocus
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Hire: Ocular Therapeutix Strengthens Leadership with Key Payer Access Executive - Stock Titan
Key Trends Shaping the Future of Ocular Implants Market:Ocular Therapeutix Launches Clinical Trial For Axit... - WhaTech
William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - MSN
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Hypertension Pipeline Analysis and Clinical Trials - openPR.com
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts - Benzinga
William Blair starts Ocular Therapeutix stock with Outperform By Investing.com - Investing.com Canada
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
William Blair Initiates Ocular Therapeutix With Outperform Rating - marketscreener.com
Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment - TipRanks
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care - Investing.com India
How to Take Advantage of moves in (OCUL) - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Ocular Therapeutix™ to Participate in Two Investor Conferences in April - The Manila Times
Exclusive: Ocular Therapeutix Leadership Sets Major Investor Presentations for April - Stock Titan
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - simplywall.st
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq
Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com
RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
Ocular rises as Needham issues new Buy on lead candidate - MSN
When (OCUL) Moves Investors should Listen - news.stocktradersdaily.com
Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus
Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL.com
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target - MarketScreener
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Ocular Therapeutix initiated with a Buy at Needham - TipRanks
Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia
Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World
Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World
Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire
0.92%
大文字化:
|
ボリューム (24 時間):